rd_hands

Shares in Celldex halve in value as it discontinues trial of brain cancer drug

pharmafile | March 8, 2016 | News story | Manufacturing and Production, Research and Development Cancer, Celldex, research 

Shares in Celldex Therapeutics (Nasdaq: CLDX) more than halved in value on the Nasdaq Monday as the company said independent regulators have recommended the discontinuation of late-stage trial of its brain cancer drug following disappointing study results.

Shares in the company closed at $3.79, down nearly 54% on the Nasdaq Monday. 

The company said it received the data for its Rintega (rindopepimut) on Friday, March 4, and is in the process of reviewing the results.

Anthony Marucci, chief executive of Celldex Therapeutics, said, “We are extremely disappointed for patients that the ACT IV study was not successful. On behalf of Celldex, I want to express our gratitude to the ACT IV investigators, patients and families who participated in this trial. While this is certainly not the desired outcome, we remain steadfast believers in the power of immunotherapy to transform the future of cancer treatment.”

Celldex currently has seven company-led clinical trials across five product candidates ongoing. The company expects to report data from a number of these studies over the next three to 18 months, including a registration study in triple negative breast cancer and a number of Phase I and II cancer immunotherapy combination trials.    

Anjali Shukla            

Related Content

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …

Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment

Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

Latest content